19.76
Structure Therapeutics Inc Adr stock is traded at $19.76, with a volume of 2.31M.
It is up +0.25% in the last 24 hours and up +17.76% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$19.71
Open:
$20
24h Volume:
2.31M
Relative Volume:
2.66
Market Cap:
$1.14B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-8.9009
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
+3.24%
1M Performance:
+17.76%
6M Performance:
-12.14%
1Y Performance:
-47.82%
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(628) 229-9277
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GPCR
Structure Therapeutics Inc Adr
|
19.76 | 1.16B | 0 | -100.44M | -105.32M | -2.22 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-02-25 | Initiated | Citigroup | Buy |
Feb-28-25 | Initiated | William Blair | Outperform |
Jan-08-25 | Initiated | Stifel | Buy |
Dec-04-24 | Initiated | H.C. Wainwright | Buy |
Sep-23-24 | Initiated | Morgan Stanley | Overweight |
May-21-24 | Initiated | JP Morgan | Overweight |
Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
Jul-27-23 | Initiated | Piper Sandler | Overweight |
May-25-23 | Resumed | Jefferies | Buy |
Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
Feb-28-23 | Initiated | Guggenheim | Buy |
Feb-28-23 | Initiated | Jefferies | Buy |
Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Obesity Drug Developer Structure Therapeutics to Present at Major Healthcare Conferences in September - Stock Titan
Layoff Tracker: Novartis Continues Cutting Spree With 58 Sacked in New Jersey - BioSpace
American Century Companies Inc. Has $8.83 Million Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Invesco Ltd. Boosts Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Analyzing Leap Technology (OTCMKTS:LPTC) and Molina Healthcare (NYSE:MOH) - Defense World
Promotora de Informaciones (OTCMKTS:PRISY) Trading 20.3% Higher – Still a Buy? - Defense World
ArcelorMittal South Africa (OTCMKTS:AMSIY) Trading Down 23.2% – What’s Next? - Defense World
Enterprise Group (TSE:E) Given a C$2.42 Price Target at Fundamental Research - Defense World
Culp (CULP) to Release Quarterly Earnings on Wednesday - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Buy” by Brokerages - Defense World
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - Bergen Record
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (TARA), Annexon Biosciences (ANNX) and Agilent (A) - The Globe and Mail
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform - MarketScreener
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors - The Motley Fool
Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity - PR Newswire
Structure Therapeutics’ SWOT analysis: oral GLP-1 stock faces pivotal phase - Investing.com
SEED Therapeutics Named Finalist for 2025 Prix Galien USA 'Best Start-Up” Award - The Manila Times
Can Structure Therapeutics’ (GPCR) Aggressive Funding Moves Accelerate Its Obesity Drug Ambitions? - Yahoo Finance
ABSSSI Pipeline 2025: Detailed Clinical Trials - openPR.com
Up 23% to 132%, There's Still Time to Buy These 3 Stocks - The Globe and Mail
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan
FY2025 EPS Estimates for GPCR Lowered by Cantor Fitzgerald - Defense World
William Blair Has Bearish Forecast for GPCR Q3 Earnings - Defense World
FY2025 EPS Estimates for GPCR Decreased by HC Wainwright - Defense World
Leerink Partnrs Has Negative Forecast for GPCR Q3 Earnings - Defense World
Leerink Partnrs Issues Negative Outlook for GPCR Earnings - Defense World
PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating - TipRanks
Why Is Everyone Talking About UnitedHealth Group Stock? - The Globe and Mail
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - AOL.com
Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks
High demand expected for new daily weight loss pill - inkl
Lilly's obesity pill lags Novo's Wegovy injection in key trial - Reuters
Structure Therapeutics (GPCR) to Release Quarterly Earnings on Thursday - Defense World
Structure Therapeutics Reports Q2 2025 Financial Results - TipRanks
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - The Manila Times
The GLP-1 Arms Race: Emerging Innovators and Capital Efficiency in the Obesity Drug Gold Rush - AInvest
Oral GLP-1 Drug Developer Structure Therapeutics Advances Multiple Obesity Trials with $786M War Chest - Stock Titan
Structure Therapeutics Inc ADR (GPCR) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Eli Lilly & Co (LLY) and Avantor (AVTR) - The Globe and Mail
2 Beaten-Down Stocks With Incredible Upside Potential - AOL.com
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Eli Lilly & Co (LLY) and Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Chefs’ Warehouse (NASDAQ:CHEF) Reaches New 52-Week High After Better-Than-Expected Earnings - Defense World
Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $76.17 - Defense World
Brookfield (NYSE:BN) Upgraded at National Bank Financial - Defense World
Camden National (NASDAQ:CAC) Stock Price Down 7.6% Following Weak Earnings - Defense World
Century Lithium (OTC:CYDVF) Shares Down 2.6% – What’s Next? - Defense World
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 0.9% – Here’s What Happened - Defense World
HCM Acquisition (NASDAQ:HCMA) Stock Price Down 3.4% – Here’s Why - Defense World
DeFi Technologies (OTC:DEFTF) Trading 20% Higher – What’s Next? - Defense World
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):